DK2117571T3 - Urokinase-type plasminogen activator receptor epitope - Google Patents

Urokinase-type plasminogen activator receptor epitope Download PDF

Info

Publication number
DK2117571T3
DK2117571T3 DK07862653.8T DK07862653T DK2117571T3 DK 2117571 T3 DK2117571 T3 DK 2117571T3 DK 07862653 T DK07862653 T DK 07862653T DK 2117571 T3 DK2117571 T3 DK 2117571T3
Authority
DK
Denmark
Prior art keywords
upar
antibody
human
cells
binding
Prior art date
Application number
DK07862653.8T
Other languages
Danish (da)
English (en)
Inventor
Graham Parry
Andrew P Mazar
Original Assignee
Monopar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc filed Critical Monopar Therapeutics Inc
Application granted granted Critical
Publication of DK2117571T3 publication Critical patent/DK2117571T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK07862653.8T 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope DK2117571T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11
PCT/US2007/025105 WO2008073312A2 (en) 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2117571T3 true DK2117571T3 (en) 2017-05-08

Family

ID=39512272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07862653.8T DK2117571T3 (en) 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope

Country Status (9)

Country Link
US (1) US8105602B2 (enExample)
EP (1) EP2117571B1 (enExample)
JP (2) JP2010512324A (enExample)
CA (1) CA2671971C (enExample)
DK (1) DK2117571T3 (enExample)
ES (1) ES2636451T3 (enExample)
PL (1) PL2117571T3 (enExample)
PT (1) PT2117571T (enExample)
WO (1) WO2008073312A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1765397T3 (pl) * 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
WO2008073312A2 (en) 2006-12-08 2008-06-19 Attenuon, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
MX2012006593A (es) * 2009-12-09 2012-06-28 Bayer Pharma AG Anticuerpos anti-c4.4a y usos de los mismos.
WO2011100620A2 (en) * 2010-02-12 2011-08-18 The Regents Of The University Of California Upar binding agents and methods of use thereof
CA2821372A1 (en) * 2010-12-22 2012-06-28 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Upar-antagonists and uses thereof
JP2014529581A (ja) 2011-08-05 2014-11-13 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ 構成的に活性なｕＰＡＲバリアントならびに阻害抗体の生成および単離へのそれの使用
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
JP6438474B2 (ja) * 2013-08-01 2018-12-12 ザ ジェネラル ホスピタル コーポレイション 非グリコシル化ｓｕＰＡＲバイオマーカー及びその使用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
EP4341296A4 (en) * 2021-05-21 2025-07-30 Northstar Medical Tech Llc RADIOPHARMACEUTICAL PRODUCT TARGETING THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
US20250296999A1 (en) * 2022-03-07 2025-09-25 Rush University Medical Center Novel Treatment of Diabetes and Kidney Disease by Inhibition of D2D3 a Proteolytic UPAR
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院（深圳福田） 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026019458A1 (en) 2024-07-19 2026-01-22 Monopar Therpeutics, Inc Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5891664A (en) 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
DE69033653T2 (de) 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
DE69133049T2 (de) 1990-10-18 2003-01-02 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Antikörper gegen den urokinaserezeptor und ihre verwendung
US5561220A (en) 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
EP0642354A4 (en) 1991-11-18 1995-07-12 Univ Michigan METHOD FOR DETECTING AND INSULATING uPA-R AND INHIBITING THE BOND uPA WITH uPA-R.
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
ATE190501T1 (de) 1992-05-28 2000-04-15 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
EP1992633A1 (en) 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
ATE361096T1 (de) 2001-01-25 2007-05-15 San Raffaele Centro Fond Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
EP2360476B1 (en) 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
AU2003216512A1 (en) 2002-03-18 2003-10-08 Dyax Corporation Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
WO2005048822A2 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7541159B2 (en) 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
EP1851543A2 (en) * 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2008073312A2 (en) 2006-12-08 2008-06-19 Attenuon, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Also Published As

Publication number Publication date
EP2117571A2 (en) 2009-11-18
WO2008073312B1 (en) 2008-12-18
CA2671971C (en) 2021-03-30
WO2008073312A2 (en) 2008-06-19
PL2117571T3 (pl) 2017-08-31
US20080199476A1 (en) 2008-08-21
EP2117571A4 (en) 2010-08-04
JP6019457B2 (ja) 2016-11-02
JP2014224134A (ja) 2014-12-04
WO2008073312A3 (en) 2008-10-30
JP2010512324A (ja) 2010-04-22
ES2636451T3 (es) 2017-10-05
CA2671971A1 (en) 2008-06-19
PT2117571T (pt) 2017-06-14
US8105602B2 (en) 2012-01-31
EP2117571B1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
EP2117571B1 (en) Urokinase-type plasminogen activator receptor epitope
CA2568428C (en) Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
JP7524065B2 (ja) 抗ｔｉｇｉｔ抗体及びその使用
US8541565B2 (en) Polynucleotide encoding anti-CD14 antibody fusion protein
KR100951432B1 (ko) 혈액 응고를 억제하기 위한 항체 및 이의 사용 방법
KR101960004B1 (ko) Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법
CN111788228A (zh) 抗密蛋白18.2抗体及其用途
EP2863948B1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
JPH07501806A (ja) ヒトｐｄｇｆベータ・レセプタに対する阻害性免疫グロブリン・ポリペプチド
CA2714657C (en) Anti-adam-15 antibodies and utilization of the same
US20240239873A1 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
US10640550B2 (en) Monoclonal antibody neutralizing infectivity of all ebola viruses
HK40094577B (en) Anti-claudin 18.2 antibodies and uses thereof
HK40094578B (en) Anti-claudin 18.2 antibodies and uses thereof
HK40094577A (zh) 抗密蛋白18.2抗体及其用途
HK40094578A (en) Anti-claudin 18.2 antibodies and uses thereof
CN118359718A (zh) 抗cd93抗体及其应用